Abstract 250P
Background
Seminoma is the most common type of germ cell tumors representing 95% of all testicular neoplasm with mean age at diagnosis of 39 years. The standard treatment modality for stage I/II is orchidectomy with high cure rate.There is an active debate regarding the use of adjuvant therapy in stage I/II due to the high relapse rate and potential for overtreatment with serious systemic side effects. The aim of this study is to assess the impact of adjuvant treatment in stage I and stage II seminoma comparing the young and adolescents to older age groups.
Methods
Data of 11718 patients diagnosed with seminoma stage I/II were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2020. They were grouped by age at diagnosis into younger than 25 years (young age group), 25 to 49 years ( middle age group) and older than 50 years (old age group). SPSS 23 was used for data analysis, Kaplan-Meier curve and log rank test for survival analysis.
Results
Patients treated surgically with no systemic therapy had 5-year relative survival of 99,4% compared to adjuvant chemotherapy (98.3%) and adjuvant radiotherapy(100%), P<0.0001. The middle age group had quite similar 5-year relative survival compared to the young age group and the elderly (99.5%, 99.3% and 99%; P<0.0001). In the young age group the 5-year relative survival was 99.9% with orchidectomy, 97.4% with adjuvant chemotherapy and 100% with adjuvant radiotherapy (p <0.0001). In the middle age group, the 5-year relative survival was 99.2% with surgery with no systemic therapy, 98.4% with adjuvant chemotherapy and 99,9% with adjuvant radiotherapy (p <0.0001) while the old age group had 5-year relative survival of 98.9% for orchidectomy, 97.5% with adjuvant chemotherapy and 99.6% with adjuvant radiotherapy(p <0.0001).
Conclusions
The use of adjuvant chemotherapy and radiotherapy for clinical stage I and stage II testicular seminoma came statistically significant. However, adjuvant systemic therapy has very limited survival benefit compared to surgical management with no systemic therapy which discourage the use of adjuvant therapy for less systemic side effects with similar overall survival across different age groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract